Human Genome Sciences
(Public, NASDAQ:HGSI) Watch this stockFind more results for
HGSI
Advertisement
Events
Jan 11, 2010
JPMorgan Healthcare Conference
- 3:00PM EST -
Dec 15, 2009
Deutsche Bank Securities Biotech Boston Confab Conference
- 12:00PM EST -
Dec 2, 2009
Piper Jaffray Healthcare Conference
- 11:30AM EST -
Nov 18, 2009
Lazard Capital Healthcare Conference
Oct 29, 2009
Q3 2009 Earnings Release
Oct 20, 2009
BENLYSTA and the BLISS-52 Trial Results Discussion/Q&A -
Oct 5, 2009
JMP Securities Healthcare Focus Conference
Sep 21, 2009
UBS Global Life Sciences Conference
Sep 14, 2009
Morgan Stanley Global Healthcare Conference
Sep 10, 2009
Robert W. Baird & Co., Inc. Health Care Conference
|
More events from AOL Finance »
|
Key stats and ratios
| Q3 (Sep '09) | 2008 | |
| Net profit margin | -260.18% | -505.79% |
| Operating margin | -201.57% | -526.94% |
| EBITD margin | - | -482.84% |
| Return on average assets | -23.55% | -30.18% |
| Return on average equity | -173.88% | - |
| Employees | 880 | - |
Address
14200, Shady Grove Road
Rockville, MD 20850-7464
United States - Map
+1-301-3098504 (Phone)
+1-301-3098512 (Fax)
Rockville, MD 20850-7464
United States - Map
+1-301-3098504 (Phone)
+1-301-3098512 (Fax)
Website links
Company website:
http://www.hgsi.com/
http://www.hgsi.com/
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com
Human Genome Sciences discussed on blogs
Ranking 700+ Mid-Cap Stocks by Profit Margin - NASD100.com - Daily ...
- Investor's Resources
- NASD100.com - Daily Stock Rankings
- Nov 20, 2009
Lupus Drug Benlysta by Human Genome Sciences and GlaxoSmithKline ...
- Elizabeth Haggar
- CEOWORLD Magazine
- Nov 2, 2009
The Unusual Suspects (BEAT, CIT, CIT-PZ, GNW, GFIG, HGSI, GSK, MCO ...
- 247wallst
- 24/7 Wall St.
- Nov 1, 2009
Human Genome Sciences discussions
View all discussions »Description
Human Genome Sciences (HGS)is a commercially focused biopharmaceutical company. The Company has three products in late-stage clinical development: Albuferon for chronic hepatitis C, LymphoStat-B for systemic lupus erythematosus and ABthraxtm for inhalation anthrax. Albuferon and LymphoStat-B are progressing toward commercialization. In December 2008, the Company reported that Albuferon met its primary endpoint in the first of two Phase III clinical trials in chronic hepatitis C. HGS also has several drugs in earlier stages of clinical development for the treatment of cancer, led by its TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins.
Officers and directors
| Argeris N. Karabelas Ph.D. | Chairman of the Board | |
| H. Thomas Watkins | President, Chief Executive Officer, Director | |
| Timothy C. Barabe | Chief Financial Officer, Senior Vice President | |
| James H. Davis J.D., Ph.D. | Executive Vice President, General Counsel, Secretary | |
| David C. Stump M.D. | Executive Vice President - Research and Development | |
| Barry A. Labinger | Executive Vice President, Chief Commercial Officer | |
| Susan D. Bateson | Senior Vice President - Human Resources | |
| Curran M. Simpson | Senior Vice President - Operations | |
| Juergen Drews M.D., Ph.D. | Director | |
| Richard J. Danzig | Director |